Articles

Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinom...

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma

Record identifier

TN_cdi_proquest_miscellaneous_1620587094

Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1620587094

Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma

Full title

Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma

Publisher

Boston: Springer US

Journal title

Annals of surgical oncology, 2014, Vol.21 (13), p.4351-4358

Record Identifier

TN_cdi_proquest_miscellaneous_1620587094

Language

English

Formats

Publication information

Publisher

Boston: Springer US

More information

SCOPE AND CONTENTS

Contents

Background
Baseline carbohydrate antigen 19-9 (CA 19-9) is a useful prognostic marker in pancreatic ductal adenocarcinoma (PDA); however, data on the significance of a change in CA 19-9 following neoadjuvant therapy are lacking.
Methods
All patients receiving neoadjuvant therapy for PDA from July 2010 to February 2013 were retrospectively...

ALTERNATIVE TITLES

Full title

Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_proquest_miscellaneous_1620587094

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1620587094

OTHER IDENTIFIERS

ISSN

1068-9265

E-ISSN

1534-4681

DOI

10.1245/s10434-014-3842-z

How to access this item

Online

1 item

How to access?

Login with a Library card